Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3447-3453

  Pontes, Thaís Brilhante ^a   Chen, Elizabeth Suchi ^a   Gigek, Carolina Oliveira ^a   Calcagno, Danielle Queiroz ^a   Wisnieski, Fernanda ^a   Leal, Mariana Ferreira ^a   Demachki, Samia ^b   Assumpção, Paulo Pimentel ^b   Artigiani, Ricardo ^a   Lourenço, Laércio Gomes ^a   Burbano, Rommel Rodriguez ^b   Arruda Cardoso Smith, Marília ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

DNA methylation; Gastric cancer; Gene expression; Methyl binding domain proteins

Indexed keywords

BISULFITE; MESSENGER RNA; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 3; TRANSCRIPTION FACTOR; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER;

ADULT; AGED; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84898801197     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1455-y     Document Type: Article

References (47)

1. Jemal A et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17-25. e1-3.
2. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266(2):99-115.
3. Calcagno DQ et al. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 2013;19(8):1182-92.
4. Gigek CO et al. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4(3):279-94.
5. Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma. 2009;118(5):549-65.
6. Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem. 2002;277(38):35434-9.
7. Zhang Y et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999;13(15):1924-35.
8. Le Guezennec X et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006;26(3):843-51.
9. Ballestar E et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003;22(23):6335-45.
10. Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer. 2011;11(8):588-96.
11. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Immunol Scand. 1965;64:31-49.
12. Wisnieski F et al. Reference genes for quantitative RT-PCR data in gastric tissues and cell lines. World J Gastroenterol. 2013;19(41):7121-8.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi:10.1006/meth.2001.1262.
14. Carr IM et al. Sequence analysis and editing for bisulphite genomic sequencing projects. Nucleic Acids Res. 2007;35(10):e79.
15. Farre D et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31(13):3651-3.
16. Messeguer X et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333-4.
17. Lopez-Serra L et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene. 2008;27(25):3556-66.
18. Parry L, Clarke AR. The roles of the methyl-CpG binding proteins in cancer. Cancer Gene Ther. 2011;2(6):618-30.
19. Sansom OJ, Maddison K, Clarke AR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol. 2007;4(5):305-15.
20. Amir RE et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185-8.
21. Calcagno DQ et al. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 2013;19(8):1182-92.
22. Muller-Tidow C et al. Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer. 2001;85(8):1168-74.
23. Kanai Y et al. Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun. 1999;264(3):962-6.
24. Maekita T et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12(3 Pt 1):989-95.
25. Lima EM et al. Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res. 2008;41(6):539-43.
26. Gigek CO et al. Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm IGF Res. 2010;20(3):234-8.
27. Leal MF et al. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from northern Brazil. World J Gastroenterol. 2007;13(18):2568-74.
28. Gigek CO et al. hTERT methylation and expression in gastric cancer. Biomarkers. 2009;14(8):630-6.
29. Angrisano T et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 2006;34(1):364-72.
30. Chatagnon A et al. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis. 2009;30(1):28-34.
31. Hendrich B et al. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 2001;15(6):710-23.
32. Kaji K et al. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat Cell Biol. 2006;8(3):285-92.
33. Aguilera C et al. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature. 2011;469(7329):231-5.
34. Sato M et al. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21(31):4822-9.
35. Liu C et al. Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference. BMC Cancer. 2008;8:121.
36. Luo G et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol Ther. 2009;8(7):594-8.
37. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998;18(11):6538-47.
38. Gunther K et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 2013;41(5):3010-21.
39. Brackertz M et al. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J Biol Chem. 2002;277(43):40958-66.
40. Tatematsu KI, Yamazaki T, Ishikawa F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells. 2000;5(8):677-88.
41. Watabe Y et al. Aryl hydrocarbon receptor functions as a potent coactivator of E2F1-dependent trascription activity. Biol Pharm Bull. 2010;33(3):389-97.
42. Xanthoulis A, Tiniakos DG. E2F transcription factors and digestive system malignancies: how much do we know? World J Gastroenterol. 2013;19(21):3189-98.
43. Consortium EP et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
44. Chen YJ et al. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol. 2012;18(29):3849-61.
45. Yuan K et al. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Am J Gastroenterol. 2013;145(4):853-64. e9.
46. Zhang X et al. MicroRNA-373 is upregulated and targets TNFAIP1 in human gastric cancer, contributing to tumorigenesis. Oncol Lett. 2013;6(5):1427-34.
47. Liu K et al. Increased expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res. 2012;40(2):467-74.